MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Sanofi

Uždarymo kaina

54.37 -2

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

54.32

Max

55.44

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-2.3B

499M

Pardavimai

-6.5B

7.6B

P/E

Sektoriaus vid.

23.205

63.778

Pelnas, tenkantis vienai akcijai

0.682

Dividendų pajamingumas

3.67

Pelno marža

6.539

Darbuotojai

82,878

EBITDA

-3.7B

563M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+16.75% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

3.67%

2.39%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-1.5B

136B

Ankstesnė atidarymo kaina

56.37

Ankstesnė uždarymo kaina

54.37

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Sanofi Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-03-20 06:43; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi to Acquire Autoimmune Disease Treatment From Dren Bio for Up to $1.9 Billion

2025-02-03 13:19; UTC

Įsigijimai, susijungimai, perėmimai

L'Oreal to Sell $3.1 Billion Stake in Sanofi Back to Pharma Group -- Update

2025-02-03 09:31; UTC

Įsigijimai, susijungimai, perėmimai

Correction to L'Oreal article

2025-02-03 07:09; UTC

Įsigijimai, susijungimai, perėmimai

L'Oreal Agrees to Sell Back 2.3% Stake in Sanofi for $3.1 Billion

2025-01-30 11:09; UTC

Uždarbis

Correction to Sanofi Article

2025-01-30 06:47; UTC

Uždarbis

Sanofi Issues $5.2 Billion Share Buyback; Expects Sales, Core Earnings Growth

2025-03-20 06:05; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: Deal Seeks to Broaden Immunology Pipeline

2025-03-20 06:05; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi to Make Potential Future Payments Totaling $1.3B Upon Reaching Milestones

2025-03-20 06:04; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi to Pay $600M Upfront

2025-03-20 06:02; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi to Buy Dren Bio's Bispecific Myeloid Cell Engager

2025-03-20 06:00; UTC

Įsigijimai, susijungimai, perėmimai

Press Release: Sanofi To Acquire Dren Bio's Bispecific Myeloid Cell Engager For Deep B-cell Depletion, Broadening Immunology Pipeline >SAN.FR

2025-02-19 06:35; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: Transaction Remains Subject to Obtaining Customary Regulatory Approvals

2025-02-19 06:34; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: Closing Is Expected to Take Place in 2Q at the Earliest

2025-02-19 06:34; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: Terms of Transaction Remain Unchanged From Those Previously Disclosed

2025-02-19 06:33; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi to Remain Significant Shareholder in Opella Consumer Business

2025-02-19 06:33; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: Bpifrance to Participate as Minority Shareholder With 2% Stake in Opella

2025-02-19 06:33; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: This Follows Completion of Required Social and Corporate Procedures

2025-02-19 06:32; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi Signs Deal for Sale of 50% Controlling Stake in Opella to CD&R

2025-02-19 06:31; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi, CD&R Sign Opella Share Purchase Agreement

2025-02-03 06:37; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi Says Transaction Is Part of Its Share Buyback Program

2025-02-03 06:35; UTC

Įsigijimai, susijungimai, perėmimai

L'Oreal: Sale Should Be Finalized in Coming Days

2025-02-03 06:35; UTC

Įsigijimai, susijungimai, perėmimai

L'Oreal: Transaction Will Optimize Balance Sheet, Diversify Financing Sources

2025-02-03 06:34; UTC

Įsigijimai, susijungimai, perėmimai

L'Oreal Says It Remains Important Sanofi Shareholder, Fully Supports Strategy

2025-02-03 06:33; UTC

Įsigijimai, susijungimai, perėmimai

L'Oreal Will Own 7.2% of Sanofi's Capital, 13.1% of Voting Rights After Transaction

2025-02-03 06:32; UTC

Įsigijimai, susijungimai, perėmimai

L'Oreal Selling 2.3% Stake in Sanofi for EUR101.50 a Share

2025-02-03 06:31; UTC

Įsigijimai, susijungimai, perėmimai

L'Oreal to Sell Sanofi Stake for EUR3B

2025-02-03 06:31; UTC

Įsigijimai, susijungimai, perėmimai

L'Oreal to Sell Sanofi Stake Back to Sanofi

2025-01-30 10:47; UTC

Rinkos pokalbiai
Uždarbis

Sanofi's Buyback and Increased R&D Spending Are Positive -- Market Talk

2025-01-30 10:31; UTC

Rinkos pokalbiai
Uždarbis

Sanofi's Lung Drug Beyfortus Sales Beat Stands Out Among 4Q Results -- Market Talk

2025-01-30 06:32; UTC

Svarbiausios naujienos
Uždarbis

Sanofi Issues $5.2 Bln Share Buyback; Expects Sales, Core Earnings Growth

Akcijų palyginimas

Kainos pokytis

Sanofi Prognozė

Kainos tikslas

By TipRanks

16.75% į viršų

12 mėnesių prognozė

Vidutinis 64.75 USD  16.75%

Aukščiausias 67 USD

Žemiausias 63 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sanofi kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

6 ratings

3

Pirkti

3

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

54.84 / 58.29Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Weak Bullish Evidence

Ilgalaikis periodas

Strong Bullish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.